MacroGenics, Inc.

356269 Days Left

Class Action Period:
March 07, 2024 - May 09, 2024

Lead Plaintiff Deadline:
January 01, 3000

Case Form

Find Out if You Potentially Qualify for a Financial Reward by filling out the form.

First Name

Last Name

Phone

Street Address

City

State

Zip

Shares Purchased

Purchase Date

Estimated Loss

The submission of this form does not create an attorney-client relationship.

Allegations

During the class period, Defendants made material misrepresentations about the safety data from its TAMARACK Phase 2 study of vobramitamab duocarmazine. On May 9, 2024, the investing public learned that the drug was significantly more dangerous than defendants had previously represented. Following this news, MGNX’s stock declined 77.4% due to a drop of $11.36/share.

Eligibility

In order to be included in the lawsuit, you must have incurred a loss on shares of MacroGenics purchased during the class period listed above.

Lead Plaintiff Deadline

If you suffered a loss in MacroGenics during the relevant time frame, you have until January 01, 3000 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.